96.11USD-12.76%Mkt Cap: 7.58B USDP/E: —Last update: 2026-06-01
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to ad…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap7.58B USD
Enterprise Value7.43B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-425.38M USD
Revenue/Share—
Last Price96.11 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees234
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-26.97
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B7.41
EPS (TTM)-6.06
EPS (Forward)-4.09
52W Range
71.1360% of range113.01
52W High113.01 USD
52W Low71.13 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-34.08%
ROA-30.11%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-275.21M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-2.38%
Net Debt-1.29B USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio16.14
Quick Ratio15.88
Book Value/Sh14.89 USD
Cash/Share16.30 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)144.52 USD
Target Range116.00 USD – 189.00 USD
# Analysts19
Ownership
Shares Out.73.56M
Float49.00M
Insiders2.76%
Institutions113.24%
Short Interest
Short Ratio8.5d
Short % Float10.44%
Short % Out.6.21%
Shares Short4.90M
Short (prev mo.)4.59M
Technical
SMA 50102.65 (-6.4%)
SMA 20097.12 (-1.0%)
Beta1.15
S&P 52W Chg27.94%
Avg Vol (30d)579.03K
Avg Vol (10d)522.83K
Technical Indicators
RSI (14)63.6
MACD1.1096
MACD Signal0.2927
MACD Hist.+0.8169
BB Upper109.41 USD
BB Middle103.61 USD
BB Lower97.81 USD
BB Width11.19%
ATR (14)3.591 USD
Vol Ratio (20d)0.98x